AAAAAA

   
Results: 1-25 | 26-50 | 51-75 | 76-93
Results: 1-25/93

Authors: LISSONI P ROVELLI F BRIVIO O FUMAGALLI L
Citation: P. Lissoni et al., CIRCADIAN SECRETIONS OF IL-2, IL-12, IL-6 AND IL-10 IN RELATION TO THE LIGHT DARK RHYTHM OF THE PINEAL HORMONE MELATONIN IN HEALTHY HUMANS/, Natural immunity, 16(1), 1998, pp. 1-5

Authors: LISSONI P GIANI L ZERBINI S TRABATTONI P ROVELLI F
Citation: P. Lissoni et al., BIOTHERAPY WITH THE PINEAL IMMUNOMODULATING HORMONE MELATONIN VERSUS MELATONIN PLUS ALOE-VERA IN UNTREATABLE ADVANCED SOLID NEOPLASMS, Natural immunity, 16(1), 1998, pp. 27-33

Authors: LISSONI P MANDALA M FUMAGALLI L ARDIZZOIA A BARNI S
Citation: P. Lissoni et al., CANCER BIOTHERAPY OF UNTREATABLE ADVANCED SOLID TUMOR PATIENTS WITH THE PINEAL HORMONE MELATONIN (MLT) PLUS IL-2 OR SOMATOSTATIN ANALOGS - A CASE-CONTROL STUDY, Annals of oncology, 9, 1998, pp. 714-714

Authors: FUMAGALLI L LISSONI P BARNI S BRIVIO F GIANI L
Citation: L. Fumagalli et al., IMMUNOTHERAPY WITH LOW-DOSE IL-2 PLUS MELATONIN (MLT) IN THE TREATMENT OF ELDERLY ADVANCED CANCER-PATIENTS, Annals of oncology, 9, 1998, pp. 68-68

Authors: LISSONI P MENGO S MANDALA M MAURI E BRIVIO F ROVELLI F CONFALONIERI G LONGARINI R BONFANTE A FOLLI D MEREGALLI S BARNI S TANCINI G GIANI L
Citation: P. Lissoni et al., PHYSIOPATHOLOGY OF IL-12 IN HUMAN SOLID NEOPLASMS - BLOOD-LEVELS OF IL-12 IN EARLY OR ADVANCED CANCER-PATIENTS, AND THEIR VARIATIONS WITH SURGERY AND IMMUNOTHERAPY, Journal of biological regulators and homeostatic agents, 12(1-2), 1998, pp. 38-41

Authors: BRACZKOWSKI R ZUBELEWICZ B ROMANOWSKI W LISSONI P BRIVIO F
Citation: R. Braczkowski et al., POSSIBLE BIOLOGICAL INDICATORS OF THE RESPONSE TO RECOMBINANT TUMOR-NECROSIS-FACTOR-ALPHA IN PATIENTS WITH ADVANCED NEOPLASMS, Journal of experimental & clinical cancer research, 17(3), 1998, pp. 349-354

Authors: BARNI S LISSONI P MEREGALLI S ARDIZZOIA A MENGO S MUSCO F MERLINI D TANCINI G
Citation: S. Barni et al., CLINICAL EFFICACY OF THE AROMATASE INHIBITOR ANASTROZOLE IN RELATION TO PROLACTIN SECRETION IN HEAVILY PRETREATED METASTATIC BREAST-CANCER, Tumori, 84(1), 1998, pp. 45-47

Authors: LISSONI P MANDALA M ROVELLI F GIANI L BARNI S MAURI E TANCINI G FUMAGALLI L DIFELICE G MAIORCA F MEREGALLI S
Citation: P. Lissoni et al., EFFECT OF INTERLEUKIN-12 IMMUNOTHERAPY ON ENDOGENOUS SECRETION OF INTERLEUKIN-2 IN METASTATIC CANCER-PATIENTS, International journal of immunotherapy, 14(2), 1998, pp. 101-104

Authors: LISSONI P BARNI S MANDALA M ROVELLI F CANGEMI G FUMAGALLI L PIRATO D VIGORE L ROSELLI MG TANCINI G VIGANO MG GIANI L
Citation: P. Lissoni et al., IMMUNOBIOLOGICAL EFFECTS OF INTERLEUKIN-2, INTERLEUKIN-12 OR INTERLEUKIN-2 PLUS INTERLEUKIN-12 IN METASTATIC CANCER-PATIENTS, International journal of immunotherapy, 14(1), 1998, pp. 41-44

Authors: LISSONI P
Citation: P. Lissoni, EFFECTS OF LOW-DOSE RECOMBINANT INTERLEUKIN-2 IN HUMAN MALIGNANCIES, The cancer journal from Scientific American, 3, 1997, pp. 115-120

Authors: LISSONI P BARNI S ARDIZZOIA A TANCINI G
Citation: P. Lissoni et al., IMMUNOTHERAPY WITH LOW-DOSE INTERLEUKIN-2 IN ASSOCIATION WITH MELATONIN AS SALVAGE THERAPY FOR METASTATIC SOFT-TISSUE SARCOMAS, Oncology Reports, 4(1), 1997, pp. 157-159

Authors: LISSONI P CAZZANIGA M BARNI S PEREGO MS BRIVIO F FUMAGALLI L TANCINI G
Citation: P. Lissoni et al., ACUTE EFFECTS OF PAMIDRONATE ADMINISTRATION ON SERUM LEVELS OF INTERLEUKIN-6 IN ADVANCED SOLID TUMOR PATIENTS WITH BONE METASTASES AND THEIR POSSIBLE IMPLICATIONS IN THE IMMUNOTHERAPY OF CANCER WITH INTERLEUKIN-2, European journal of cancer, 33(2), 1997, pp. 304-306

Authors: LISSONI P ROVELLI F PITTALIS S CASATI M PEREGO MS GRASSI MG BRIVIO F FUMAGALLI L
Citation: P. Lissoni et al., INTERLEUKIN-12 IN EARLY OR ADVANCED CANCER-PATIENTS, European journal of cancer, 33(10), 1997, pp. 1703-1705

Authors: LISSONI P TANCINI G BARNI S PAOLOROSSI F ARDIZZOIA A CONTI A MAESTRONI G
Citation: P. Lissoni et al., TREATMENT OF CANCER CHEMOTHERAPY-INDUCED TOXICITY WITH THE PINEAL HORMONE MELATONIN, Supportive care in cancer, 5(2), 1997, pp. 126-129

Authors: LISSONI P PAOLOROSSI F ARDIZZOIA A BARNI S CHILELLI M MANCUSO M TANCINI G CONTI A MAESTRONI GJM
Citation: P. Lissoni et al., A RANDOMIZED STUDY OF CHEMOTHERAPY WITH CISPLATIN PLUS ETOPOSIDE VERSUS CHEMOENDOCRINE THERAPY WITH CISPLATIN, ETOPOSIDE AND THE PINEAL HORMONE MELATONIN AS A FIRST-LINE TREATMENT OF ADVANCED NONSMALL CELL LUNG-CANCER PATIENTS IN A POOR CLINICAL STATE, Journal of pineal research, 23(1), 1997, pp. 15-19

Authors: LISSONI P ROVELLI F RIVOLTA MR FRIGERIO C MANDALA M BARNI S ARDIZZOIA A MALUGANI F TANCINI G
Citation: P. Lissoni et al., ACUTE ENDOCRINE EFFECTS OF INTERLEUKIN-12 IN CANCER-PATIENTS, Journal of biological regulators and homeostatic agents, 11(4), 1997, pp. 154-156

Authors: LISSONI P ROVELLI F MEREGALLI S FUMAGALLI L MUSCO F BRIVIO F BRIVIO O ESPOSTI G
Citation: P. Lissoni et al., MELATONIN AS A NEW POSSIBLE ANTIINFLAMMATORY AGENT, Journal of biological regulators and homeostatic agents, 11(4), 1997, pp. 157-159

Authors: LISSONI P FUMAGALLI L PAOLOROSSI F ROVELLI F ROSELLI MG MAESTRONI GJM
Citation: P. Lissoni et al., ANTICANCER NEUROIMMUNOMODULATION BY PINEAL HORMONES OTHER THAN MELATONIN - PRELIMINARY PHASE-II STUDY OF THE PINEAL INDOLE 5-METHOXYTRYPTOPHOL IN ASSOCIATION WITH LOW-DOSE IL-2 AND MELATONIN, Journal of biological regulators and homeostatic agents, 11(3), 1997, pp. 119-122

Authors: LISSONI P CAZZANIGA M TANCINI G SCARDINO E MUSCI R BARNI S MAFFEZZINI M MERONI T ROCCO F CONTI A MAESTRONI G
Citation: P. Lissoni et al., REVERSAL OF CLINICAL RESISTANCE TO LHRH ANALOG IN METASTATIC PROSTATE-CANCER BY THE PINEAL HORMONE MELATONIN - EFFICACY OF LHRH ANALOG PLUSMELATONIN IN PATIENTS PROGRESSING ON LHRH ANALOG ALONE, European urology, 31(2), 1997, pp. 178-181

Authors: LISSONI P FUMAGALLI L DIFELICE G MENGO S MAURI E MERLINI D MEREGALLI S ROVELLI F BARNI S TANCINI G
Citation: P. Lissoni et al., PROGNOSTIC-SIGNIFICANCE OF CHANGES IN IL-12 SECRETION DURING CANCER-IMMUNOTHERAPY WITH IL-2 - PRELIMINARY CONSIDERATIONS, International journal of immunotherapy, 13(1-2), 1997, pp. 17-23

Authors: LISSONI P
Citation: P. Lissoni, PROGNOSTIC MARKERS IN INTERLEUKIN-2 THERAPY, CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 11(5), 1996, pp. 285-287

Authors: LISSONI P BRIVIO F BARNI S TANCINI G ARDIZZOIA A ROVELLI F GRAMAZIO P ALDERI G ZUBELEWICZ B
Citation: P. Lissoni et al., TUMOR-NECROSIS-FACTOR-ALPHA (TNF-ALPHA) BLOOD-LEVELS IN RELATION TO THE ACTIVITY OF THE PINEAL-GLAND IN CANCER-PATIENTS, Biologicals, 24(3), 1996, pp. 214-214

Authors: LISSONI P ARDIZZOIA A BARNI S TANCINI G MUTTINI MP
Citation: P. Lissoni et al., IMMUNOTHERAPY WITH SUBCUTANEOUS LOW-DOSE INTERLEUKIN-2 PLUS MELATONINAS SALVAGE THERAPY OF HEAVILY CHEMOTHERAPY-PRETREATED OVARIAN-CANCER, Oncology Reports, 3(5), 1996, pp. 947-949

Authors: LISSONI P PITTALIS S ROVELLI F ROSELLI MG ARDIZZOIA A
Citation: P. Lissoni et al., MODULATION OF CYTOKINE PRODUCTION FROM TH2-LYMPHOCYTES AND MONOCYTES BY THE PINEAL NEUROHORMONE MELATONIN, Oncology Reports, 3(3), 1996, pp. 541-543

Authors: LISSONI P PAOLOROSSI F TANCINI G BARNI S ARDIZZOIA A BRIVIO F ZUBELEWICZ B CHATIKHINE V
Citation: P. Lissoni et al., IS THERE A ROLE FOR MELATONIN IN THE TREATMENT OF NEOPLASTIC CACHEXIA, European journal of cancer, 32A(8), 1996, pp. 1340-1343
Risultati: 1-25 | 26-50 | 51-75 | 76-93